Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
d-leucovorin is the (6R)-diastereoisomer of leucovorin (folinic acid), a reduced folate derivative. While leucovorin is typically administered as a racemic mixture of d- and l-isomers, only the l-isomer (levoleucovorin) is biologically active in the metabolic pathways that potentiate 5-fluorouracil or provide a source of reduced folates during methotrexate rescue. d-leucovorin is considered biologically inactive in these therapeutic contexts but is characterized by a significantly longer plasma half-life (approximately 7-9 hours compared to 30-60 minutes for the l-isomer). It competes with l-leucovorin for transport into cells via the reduced folate carrier (RFC1) and for renal clearance, which may lead to competitive inhibition of the active isomer's efficacy. Consequently, pure l-leucovorin formulations have been developed to avoid the potential interference caused by the d-isomer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-leucovorin.